相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease
Sayam Dubash et al.
RHEUMATOLOGY (2019)
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Secukinumab-induced subacute-cutaneous lupus erythematosus
C. Wehrmann et al.
HAUTARZT (2018)
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Desiree van der Heijde et al.
JOURNAL OF RHEUMATOLOGY (2018)
In vitro-engineered non-antibody protein therapeutics
Rudo Simeon et al.
PROTEIN & CELL (2018)
New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice
Sayam Dubash et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab
Y. Satoh et al.
LUPUS (2018)
The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling
Melissa N. Van Tok et al.
FRONTIERS IN IMMUNOLOGY (2018)
Learning from the youngsters: ixekizumab in active ankylosing spondylitis
Xenofon Baraliakos et al.
LANCET (2018)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Desiree van der Heijde et al.
LANCET (2018)
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
Christoph Molnar et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Altered cytokine expression by macrophages from HLA-B27-positive spondyloarthritis patients without evidence of endoplasmic reticulum stress
Carmen A. Ambarus et al.
RHEUMATOLOGY ADVANCES IN PRACTICE (2018)
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2018)
Cumulative retention rate of adalimumab in patients with Behcet's disease-related uveitis: a four-year follow-up study
Claudia Fabiani et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
IL-23/Th17 targeted therapies in SAPHO syndrome. A case series
Daniel Wendling et al.
JOINT BONE SPINE (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
H. Marzo-Ortega et al.
ARTHRITIS CARE & RESEARCH (2017)
The Paradox of Bone Formation and Bone Loss in Ankylosing Spondylitis: Evolving New Concepts of Bone Formation and Future Trends in Management
Marina N. Magrey et al.
CURRENT RHEUMATOLOGY REPORTS (2017)
Secukinumab-Induced Psoriasiform Eruption
Michael J. Sladden et al.
JAMA DERMATOLOGY (2017)
Secukinumab for Acrodermatitis Continua of Hallopeau
David Muggli et al.
JAMA DERMATOLOGY (2017)
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study
Francisco J. Blanco et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Group 3 Innate Lymphoid Cells in Human Enthesis
Richard J. Cuthbert et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
Helena Marzo-Ortega et al.
RMD OPEN (2017)
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka et al.
ARTHRITIS RESEARCH & THERAPY (2017)
NO DEMONSTRABLE EFFECT OF IL-23 RECEPTOR VARIANTS ON CLINICAL MEASURES AND IL23/IL-17 LEVELS IN ANKYLOSING SPONDYLITIS
J. Nossent et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
Michael Kammueller et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2017)
Anti-IL17A in Axial Spondyloarthritis-Where Are We At?
Peter P. Cheung
FRONTIERS IN MEDICINE (2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
IL-17+ γδ T cells as kick-starters of inflammation
Pedro H. Papotto et al.
NATURE IMMUNOLOGY (2017)
Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barr, syndrome after anti-TNF-α treatment? Case report and literature review
Savvas Psarelis et al.
CLINICAL RHEUMATOLOGY (2017)
The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment
H. Jethwa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2016)
A revolutionary therapeutic approach for psoriasis: bispecific biological agents
T. Torres et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Adalimumab in Patients with Active Noninfectious Uveitis
Glenn J. Jaffe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis
Jose Ramon Vidal-Castineira et al.
PLOS ONE (2016)
Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts
Oezge Uluckan et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
IL-17-producing γδ T cells enhance bone regeneration
Takehito Ono et al.
NATURE COMMUNICATIONS (2016)
Interleukin-23-Dependent/T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice
Annika Reinhardt et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis
Francesco Ciccia et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Camelid nanobodies: killing two birds with one stone
Aline Desmyter et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2015)
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
Itay Raphael et al.
CYTOKINE (2015)
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Jacob S. Lee et al.
IMMUNITY (2015)
Gut-Busters: IL-17 Ain't Afraid of No IL-23
Natasha Whibley et al.
IMMUNITY (2015)
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
Dhavalkumar D. Patel et al.
IMMUNITY (2015)
Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis
Yun Ling et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
'MHC-I-opathy'-unified concept for spondyloarthritis and Behcet disease
Dennis McGonagle et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Spinal Radiographic Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Blocking Therapy: A Prospective Longitudinal Observational Cohort Study
Fiona Maas et al.
PLOS ONE (2015)
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography
X. Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis
Xenofon Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Inflammation, new bone formation and treatment options in axial spondyloarthritis
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The critical role of interleukin-23 in spondyloarthropathy
Jonathan P. Sherlock et al.
MOLECULAR IMMUNOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Interleukin-17 Induces an Atypical M2-Like Macrophage Subpopulation That Regulates Intestinal Inflammation
Kenichiro Nishikawa et al.
PLOS ONE (2014)
In Situ Analysis of Interleukin-23-and Interleukin-12-Positive Cells in the Spine of Patients With Ankylosing Spondylitis
Heiner Appel et al.
ARTHRITIS AND RHEUMATISM (2013)
Combinatorial Control of Th17 and Th1 Cell Functions by Genetic Variations in Genes Associated With the Interleukin-23 Signaling Pathway in Spondyloarthritis
Maryaline Coffre et al.
ARTHRITIS AND RHEUMATISM (2013)
Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases
Ning Qu et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten et al.
LANCET (2013)
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci
Adrian Cortes et al.
NATURE GENETICS (2013)
Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials
Andrew D. Dick et al.
OPHTHALMOLOGY (2013)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
The multi-faceted nature of HLA class I dimer molecules
Elaine C. Campbell et al.
IMMUNOLOGY (2012)
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells
Jonathan P. Sherlock et al.
NATURE MEDICINE (2012)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
David M. Evans et al.
NATURE GENETICS (2011)
The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans
Paola Di Meglio et al.
PLOS ONE (2011)
HLA-B27 Misfolding and the Unfolded Protein Response Augment Interleukin-23 Production and Are Associated With Th17 Activation in Transgenic Rats
Monica L. Delay et al.
ARTHRITIS AND RHEUMATISM (2009)
Radiographic Findings Following Two Years of Infliximab Therapy in Patients With Ankylosing Spondylitis
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2008)
Enthesitis
Maria Antonietta D'Agostino et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2006)
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
S Aggarwal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites
M Benjamin et al.
JOURNAL OF ANATOMY (2001)
分享论文
